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Objectives/Hypothesis: Pharyngocutaneous fistulae (PCF) are known to occur in nearly one-third of patients after sal-
vage total laryngectomy (STL). PCF has severe impact on duration of admission and costs and quality of life and can even
cause severe complications such as bleeding, infection and death. Many patients need further surgical procedures. The impli-
cations for functional outcome and survival are less clear. Several studies have shown that using vascularized tissue from out-
side the radiation field reduces the risk of PCFs following STL. This review and meta-analysis aims to identify the evidence
base to support this hypothesis.
Data Sources: English language literature from 2004 to 2013
Review Methods: We searched the English language literature for articles published on the subject from 2004 to 2013.
Results: Adequate data was available to identify pooled incidence rates from seven articles. The pooled relative risk
derived from 591 patients was 0.63 (95% CI: 0.47 to 0.85), indicating that patients who have flap reconstruction/reinforce-
ment reduced their risk of PCF by one-third.
Conclusion: This pooled analysis suggests that there is a clear advantage in using vascularized tissue from outside the
radiation field in the laryngectomy defect. While some studies show a clear reduction in PCF rates, others suggest that the fis-
tulae that occur are smaller and rarely need repair.




The Veteran’s Affairs Cooperative Laryngeal Cancer
Study Group and Radiation Therapy Oncology Group
(RTOG)291-11 trials1,2 showed the efficacy of chemora-
diation (CRT) in the management of locally advanced
tumors of the larynx. With primary CRT being widely
adopted as a management strategy, there has been a
paradigm shift in the treatment of laryngeal cancer.
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With organ preservation rates between 60% and 80% at
5 years for those patients completing the therapy, there
continues to be a substantial proportion of patients who
need salvage total laryngectomy (STL), commonly due to
persistent or recurrent laryngeal cancer, second primary
tumors, and occasionally for laryngeal dysfunction or
radionecrosis.3 It is widely accepted that salvage total
laryngectomies (STLs) performed after radiation failure
are more prone to complications as compared to laryng-
ectomies performed upfront. A higher complication rate
is reported for patients who undergo STL with neck dis-
sections and flap reconstructions of mucosal defects. The
most significant complication in this regard is a phar-
yngocutaneous fistula (PCF).4 A PCF can have several
unintended consequences. It delays postoperative recov-
ery, delays function acquisition and increases hospital
stay and consequently costs. Rarely, a salivary leak can
erode into cervical or mediastinal blood vessels causing
potentially catastrophic bleeding and life-threatening
complications.
A meta-analysis of 25 studies by Paydarfar and
Birkmeyer5 demonstrated a 2.28 times increased risk of
PCF among patients who received radiation or CRT
prior to laryngectomy. Weber et al.6 published the out-
comes of 129 patients in the RTOG 91-11 trial who
needed STL. The incidence of PCF in patients who
underwent CRT was 30%, which was twice that seen in
patients who failed radiation therapy alone. Addition-
ally, the incidence of complications in the 30% of
patients who need salvage laryngectomy for failed CRT
can be as high as 50% to 60%.6–8 Complications are
more common when STLs are performed within the
first year after CRT.9 Several reports suggest that
PCFs following CRT are more likely to need surgical
repair than are those that occur after primary
laryngectomy.5,7,10
Not all studies report a higher complication rate for
STLs. This may be a reflection of the data analysis and
the variable treatment regimens employed, as well as
the year in which the laryngectomy was performed. For
instance, Grau et al.11 studied the incidence of fistula
following laryngectomy in radiation failures in the Dan-
ish Head and Neck Cancer Group (DAHANCA) trials (5,
6, and 7) over a 10-year period between 1987 and 1997.
They found a 19% incidence of PCF in 472 patients.
Multiple logistic regression analysis showed that STLs
performed in the latter years of the 10-year period,
advanced T stage and nonglottic location of primary
sites predisposed to PCF occurrence. Given the intensi-
fied (accelerated) radiotherapy schedules in the
DAHANCA 6 and 7 trials, the higher PCF incidence
may reflect more aggressive irradiation schedules in the
latter years. However, a higher proportion of advanced
tumors undergoing STL and a reduction in the number
of STLs over the 10-year period (i.e., as few as 30 STLs
performed at five different centers in 1997) may also
have contributed to the observed increase in relative
risk of fistula.
Radiotherapy and CRT not only kill tumor cells, but
also cause damage to the other tissues, including blood
vessels.12 This tissue damage causes delayed healing
after radiotherapy and CRT. Several surgical teams
have hypothesized that transferring healthy vascular-
ized tissue from outside the radiation field enhances
wound healing and reduces the incidence of wound com-
plications. Several studies have reported on the use of
vascularized tissue from outside the radiation field to
reinforce the pharyngeal repair site or to augment the
circumference by using this as a patch. The choices of
donor tissue are usually: pectoralis major myofascial
flap (PMMF), pectoralis major myocutaneous flap
(PMMC), or free flaps from various sites. While some
have been supportive of this intervention, others have
not identified an advantage. The outcome of interest, the
PCF, is not subject to a diagnostic bias and is a clean
binary outcome (presence or not of a salivary leak).
The aim of this study was to pool the available data
on PCF rates in patients after STL who received flap
cover following laryngectomy, and to quantify any bene-
fit associated with this strategy.
MATERIALS AND METHODS
Systematic Review
CRT as a strategy for advanced laryngeal cancer has been
used since the publication of the RTOG 91-11 trial,2 and general
awareness of the increased risk of PCFs following STLs from
the RTOG 91-11 cohort has been available following the publi-
cation by Weber et al.6 Both these reports were published in
2003; therefore, the English language literature from 2004 to
2013 was searched by a librarian with relevant expertise. The
following search terms were used: salvage total laryngectomy,
pharyngocutaneous fistula, salivary fistula, salivary leak, com-
plications, flap reconstruction, free flap, and pedicled flap.
International experts were also consulted. Inclusion criteria are
set out in Table I.
Statistical Analysis
Data were tabulated in Microsoft Excel, then exported for
analysis using the statistical package R Version 3.0 (The R
Foundation for Statistical Computing, Vienna, Austria).
To measure heterogeneity of the incidence data, the I2 sta-
tistic was calculated, and the data were visualized using a fun-
nel plot. A high figure for I2 implies heterogeneous data with
the converse implying homogenous data. Because the data
ranged from entirely homogenous to moderately heterogeneous,
we used an inverse variance (fixed effects) model to calculate
the pooled estimates of PCF rates. Similarly, the fixed effects
model of Mantel-Haenszel was used to calculate pooled esti-
mates of relative risk. This is the probability of fistula in the
reconstruction group, divided by the probability of the event in
the primary repair group.
TABLE I.
Inclusion Criteria.
1. The cohort should include salvage laryngectomy patients
who underwent some form of flap reconstruction to the
neopharynx, whose outcomes should be distinctly identifiable.
2. The number patients who develop pharyngocutaneous
fistula following salvage laryngectomy and flap reconstruction
should be clearly identified.
3. A clear description of flap used to reconstruct the
neopharynx should be available.




The Medline search identified 71 abstracts. Full
text was obtained wherever the abstract indicated that
vascularized tissue had been used to reconstruct the
neopharynx. After screening against the inclusion crite-
ria, 12 articles were retained. Finally, after further
exclusions as described below, seven articles were
included in the final meta-analysis. Table II summarizes
this literature on using new vascularized tissue to recon-
struct neopharyngeal defects. The commentary below
expands on some of the key findings.
Exclusions
Two articles13,14 were excluded from the analysis
because it was impossible to separate the data pertain-
ing to laryngectomy alone from those who underwent
more complex resections. Data from three other
papers15–17 despite being eligible, were also excluded for
the reasons stated below:
1. Sakai et al.13 described their experience of bringing in vascu-
larized tissue in 13 of 52 patients undergoing a STL or a sal-
vage total laryngopharyngectomy. PMMC or deltopectoral
flaps were used to reinforce the pharyngeal repair; or in
patients undergoing total laryngopharyngectomy, these flaps
were used to cover the jejunal free flap. Despite more patients
in the flap group receiving primary CRT than radiation alone
(53.8% vs. 30.8%), the PCF rate was lower in the flap group (1
patient, 7.7%) compared with the PCF rate in the nonflap
group (12 patients, 30.1%). However, we were unable to sepa-
rate out the data pertaining to STL patients in this series.
2. Sinclair et al14 summarized their experience with 137
patients who underwent laryngectomy or laryngopharyngec-
tomy with free flap reconstruction of the pharyngeal defect.
Most patients had a patch graft to augment the circumfer-
ence. The major aim of this article was to identify whether
performing a primary tracheoesophageal puncture increased
PCF rates; however, it can be gleaned from the article that,
despite a complex cohort including 32 laryngopharyngecto-
mies, the incidence of PCF in this large group was 14%. In
their discussion of results, Sinclair et al.14 are of the view
that it is the use of vascularized free flaps that has helped to
keep the rates of PCFs low in this cohort, despite the vast
majority being STLs. This article was excluded because both
primary and salvage patients belonged to the cohort, and the
data for salvage patients was not separately presented.
3. Although adequate data was present in another article,15 it
was excluded as it was determined that the patient cohort was
different from the other series: All patients had extensive
tumors fungating through the skin and were malnourished—
and seven cases also underwent partial pharyngeal resection.
4. Finally, there was overlap between patients reported in two
eligible articles16,17 and a recent multi-institutional review18
of 359 patients from seven centers. Assuming an even
recruitment, approximately 40 patients would have been rep-
resented twice in the meta-analysis, receiving double the
weighting of all others. Therefore, we conducted our meta-
analysis without the two smaller studies, although we have
reported their data for completeness.
Commentary on Surgical Methods and
Outcomes
In broad terms, surgeons have adopted two distinct
techniques when using vascularized tissue following
laryngectomy:
A.Vascularized tissue to augment the pharyn-
geal circumference by a patch graft. Withrow et al.16
compared two groups of STL patients: Seventeen
patients had free flaps to augment the pharyngeal cir-
cumference and 20 patients underwent primary closure
of the pharynx. The cutaneous paddles of the free flaps
were placed as patch grafts to supplement the anterior
pharyngeal defects following laryngectomy. This free flap
reconstruction group had a lower rate of fistula (18%)
compared with the primary closure group (50%).
Powell et al.19 detailed the course of 45 STLs:
Thirty-eight STLs 38 underwent primary closure and
seven STLs had free or pedicled flaps employed as a
patch to augment the pharyngeal closure.There were no
leaks in the group that had a flap, whereas a 26% leak
rate was evident in the primary closure group.
TABLE II.
Summary Data From the included Studies.
Author Type of Flap Reconstruction
N PCF N PCF N PCF
Total Total Primary Primary Flap Flap
Fung et al.21 Free reinforcement 41 12 27 8 14 4
Gil et al.10 PMMF reinforcement 80 19 69 16 11 3
Oosthuizen et al.27 PMMF reinforcement 10 3 2 1 8 2
Patel et al.18 Free & PMMF reinforcement & patch 359 94 99 34 260 60
Powell et al.19 Free & PMMF reinforcement & patch 45 10 38 10 7 0
Righini et al.20 PMMF reinforcement 25 5 12 4 13 1
Sousa et al.22 PMMC not specified 31 10 12 7 19 3
*Patel and Keni17 PMMF reinforcement 17 4 7 4 10 0
*Withrow et al.16 Free patch 37 13 20 10 17 3
Summary 591 153 259 80 332 73
*Shown for completeness only; most patients are also reported in Patel et al.18 Data are not included in the summary statistics or meta-analysis.
PCF5pharyngocutaneous fistulae; PMMC5pectoralis major myocutaneous flap; PMMF5pectoralis major myofascial flap.
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B.Vascularized tissue to reinforce the pharyn-
geal repair. The use of PMMF to reinforce the defect is
well described by Righini et al,20 who used the PMMF
flap to reinforce the suture line by covering it with
healthy muscle, anchored to the base of tongue, the pha-
ryngeal constrictors, and the posterior wall of the tra-
chea. This led to a 7.6% leak rate compared to 33.3%
PCF rates in those who received no flaps. Other investi-
gators have used similar techniques. Patel et al.17
reported on a series of 17 patients who underwent STL:
Seven patients were closed primarily and 10 patients
had reinforcement of the repair line with PMMF.
Although none of the patients in the PMMF group devel-
oped PCF, four of seven patients who were closed with-
out reinforcement developed fistula (P< 0.02).
Gil et al.10assessed the role of PMMF in 80 patients
who underwent STL. Of those, 69 patients were closed pri-
marily and 11 patients received a PMMF reinforcement of
the suture line. Whereas there was no difference in the
rates of PCF formation between the groups (27% vs. 24%),
eight of the 16 patients (50%) with PCF who did not receive
PMMF required a second surgical procedure for fistula clo-
sure. On the other hand, none of the patients in the PMMF
group who developed a PCF required a second operation
(P<.001), or had a hospital stay exceeding 30 days.
Fung et al.21 retrospectively compared a cohort of
14 patients who had free tissue reinforcement of the
pharyngeal suture line following STL after CRT with a
historical group of 27 patients (surgical patients of
RTOG 91-11 trial) who had primary repair alone.
Although the overall PCF rate was similar between
groups (29% in the flap group compared with 30% in the
RTOG-91-11 group) the RTOG 91-11 group had a 15%
incidence of major wound complications, while the flap
group had none. All PCFs in the flap group were minor
and needed no surgical repair, while the three in the pri-
mary repair group were considered to be major. All
patients underwent primary tracheoesophageal punc-
ture. The results of this study raise the question: Would
avoiding a primary puncture in these patients have
made a difference to the fistula rates?
Whereas most studies have specified how exactly the
flap was used to help with the neopharyngeal reconstruc-
tion, Sousa et al.22 did not describe how the PMMC flap
was inset in 19 of 31 STLs performed at their center. How-
ever, outcome data and flap use are well described, and as
this article satisfied inclusion criteria, it was included.
Pooled Estimates of Incidence
Table III summarizes the overall incidence of PCF in
all included studies and by the two surgical groups. From
all 591 patients in the seven studies, the pooled (95% con-
fidence interval) fistula rate was 26.1% (22.7 to 29.7%).
The pooled incidence for 332 patients who underwent flap
reconstruction was 22.2% (17.9 to 26.8%), but was 31.2%
(25.8 to 36.9) in 259 patients who were closed primarily
(Table III). Based on the event rates in both groups, we
estimate that the number needed to treat is 11; this
means that to prevent one fistula, 11 patients will need
vascularized flaps following STL.
Pooled Estimates Of Relative Risk
The pooled relative risk for patients who have flap
reconstruction/reinforcement was 0.63 (95% CI: 0.47 to
0.85), relative to those whose pharyngeal defects are
closed primarily (Fig. 1). In other words, the risk of fis-
tula following primary closure is approximately 50%
higher than for the flap reconstruction.
DISCUSSION
Summary of Main Results
This article lends support to the hypothesis that
employing vascularized tissue from outside the radiation
TABLE III.
Proportions of Pharyngocutaneous Fistula by Group, With Relative Risk of Fistula Between the Groups.
Author
% PCF % PCF % PCF Relative Risk
Overall Primary Flap Flap Versus Primary
Fung et al. 21 29.3 (16.1–45.5) 29.6 (13.8–50.2) 28.6 (8.4–58.1) 0.96 (0.35–2.65)
Gil et al.10 23.8 (14.9–34.6) 23.1 (13.9–34.9) 27.2 (6.0–61.0) 1.18 (0.41–3.38)
Oosthuizen et al.27 30.0 (6.7–65.2) 50.0 (1.3–98.7) 25.0 (3.2–65.1) 0.50 (0.08–3.13)
Patel et al.18 26.2 (21.7–31.1) 34.3 (25.1–44.6) 23.1 (18.1–28.7) 0.67 (0.47–0.95)
Powell et al.19 22.2 (11.2–37.1) 26.3 (13.4–43.1) 0.0 (0.0–41.0) 0.24 (0.02–3.74)
Righini et al.20 20.0 (6.8–40.7) 33.3 (9.9–65.1) 7.7 (0.2–36.0) 0.23 (0.03–1.79)
Sousa et al.22 32.3 (16.7–51.4) 58.3 (27.7–84.8) 15.8 (3.4–39.6) 0.27 (0.09–0.85)
*Patel and Keni17 23.5 (6.8–49.8) 57.1 (18.4–90.1) 0.0 (0.0–30.8) 0.08 (0.00–1.26)
*Withrow et al.16 35.1 (20.2–52.5) 50.0 (27.2–72.8) 17.6 (3.8–43.4) 0.35 (0.12–1.08)
Summary 26.1 (22.7–29.7) 31.2 (25.8–36.9) 22.2 (17.9–26.8) 0.63 (0.47–0.85)
PCF5pharyngocutaneous fistulae.
95% confidence Intervals are in brackets.
Test for heterogeneity on relative risk: X2 (6)5 5.7 (P -value50.5). No evidence for heterogeneity, thus fixed effects model used.
Summary proportions calculated using inverse variance method.
Summary relative risk calculated using Mantel-Haenszel method.
*Shown for completeness only; most patients are also reported in Patel et al.18 Data are not included in the summary statistics or meta-analysis.
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field appears to be consistently effective in reducing the
incidence of postoperative PCFs in a third of patients
who undergo STL and is a significant advantage in this
patient group.
Quality of Evidence and Potential Biases
in Review
We appreciate that this is a retrospective pooling of
case series and thus is prone to the drawbacks associated
with such studies. However, the presence or absence of
PCF is a binary outcome that is relatively immune to
measurement bias and therefore should be robust.
Comparison With Other Reviews
Patel et al.18 performed a multi-institutional retro-
spective review of 359 STL patients, grouped by closure
technique: primary closure of the defect (n599), inter-
posed free tissue (n5220) or PMMF onlay flap (n5 40).
Incidence of PCF was 34%, 25% and 15% for the primary
closure, interposed free tissue and PMMF onlay groups
respectively, with the difference in fistula duration
between primary closure and either flap technique being
statistically significant (p5 .004). For patients who
developed fistula, mean duration of fistula was signifi-
cantly prolonged with primary closure (14.0 weeks) com-
pared with pectoralis flap (9.0 weeks) and free flap (6.5
weeks). Since this is the single biggest contributor to our
own systematic review, it is no surprise that the two
reviews are in close agreement about the overall benefit
of flap techniques. However, our review captures the
international practice on this subject and confirms that
similar reductions in PCF rates are achieved (although
not achieving statistical significance owing to small sam-
ple sizes) in all the studies except one.
In patients undergoing primary laryngectomy,
Smith et al.23demonstrated a significant reduction in the
incidence of PCF by the routine addition of a PMMF to
reinforce the pharyngeal closure in a retrospective
cohort of 223 consecutive primary total laryngectomies,
from 23% to less than 1%. Similarly, in a cohort of 65
patients, Albirmawy24 used a sternocleidomastoid mus-
cle collar flap and reduced the PCF rates from 34% to
3%. Although the use of flaps25,26 is associated with
donor site morbidity, it can be anticipated that this mor-
bidity outweighed by the significant morbidity and risks
associated with PCF development.
Implications for Clinical Practice
This strategy is simple and well within the expertise
of the majority of head and neck surgical teams anywhere
in the world. Based on the studies presented, it is possible
to reduce PCF rates following STL to well below those
seen even after primary laryngectomy. The increased time
spent in the operating suite to perform a flap reconstruc-
tion may be offset by the reduction in postoperative stay
and reduced need for surgical repair of the fistula. Other
outcomes such as the need for a second surgical procedure
to close the PCF, donor site morbidity, extra costs of the
flap reconstruction and a description of the fistula as
major or minor were not analyzed as the clinical assess-
ment of the size of the fistula can vary, as can the decision
to do a second operation. However, it should be noted that
several studies10,13,20,21 indicated that surgical repair of
fistulae was almost never required in patients who
received prophylactic flap reconstruction.
It is very unlikely that an adequately powered trial
to answer this question will ever be performed, and
clinicians will have to make the best use of available
data to change practice. As the effects of the complica-
tion are severe in this vulnerable group of patients, all
the authors (despite their geographical distribution) felt
that the heterogeneity in technique was not clinically
significant, the overall effect is the same and were com-
fortable pooling data. Given the substantial reduction in
fistula rates, the benefit conferred by a vascularized tis-
sue reconstruction is strong. A multi-site, multi-author
review such as this has a powerful role to play in chang-
ing practice in the absence of high level evidence.
Implications for Research
Definitive answers concerning the functional out-
come and cost-effectiveness of routine flap reconstruction
in STL would require further study.
CONCLUSION
There is currently retrospective, but clear evidence
to support the routine use of vascularized flaps to
Fig. 1. Forest plot for relative risk of developing pharyngocutane-
ous fistula. The pooled relative risk for those patients who receive
flap reconstruction/reinforcement of the neopharynx is 0.63 (95%
confidence interval: 0.47–0.85) *Shown for completeness only;
most patients are also reported in Patel et al.18 Data are not
included in the summary statistics or meta-analysis.
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augment or bolster the pharyngeal closure following
STL as a strategy to reduce PCF. The risk of PCF in
these patients can be reduced by one-third if vascular-
ized tissue from outside the radiation field is used to
reconstruct the laryngectomy defect. The vascularized
tissue can be used to reinforce the pharyngeal repair
site or to augment the circumference of the neopharynx
by using it as a patch. While it is appreciated that flap-
related morbidity exists, the morbidity associated with a
PCF is undoubtedly greater, thus supporting the apho-
rism that “prevention is better than any subsequent
management and treatment of PCF.”
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